Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Geeta Gulati"'
Autor:
Agneta Månsson Broberg, MD, PhD, Suvi Tuohinen, MD, PhD, Tanja Skytta, MD, PhD, Jürgen Geisler, MD, PhD, þórdís Jóna Hrafnkelsdóttir, MD, PhD, Agnes Smáradóttir, Kirsten Melgaard Nielsen, MD, PhD, Birgitte V. Offersen, MD, PhD, Marianne Jarfelt, MD, PhD, Geeta Gulati, MD, PhD
Publikováno v:
JACC. CardioOncology, Vol 2, Iss 2, Pp 333-335 (2020)
Externí odkaz:
https://doaj.org/article/ecc684da6c2646beb7361c07336f2b44
Autor:
Geeta Gulati, Siri L. Heck, Helge Røsjø, Anne H. Ree, Pavel Hoffmann, Tor‐Arne Hagve, Jon Norseth, Berit Gravdehaug, Kjetil Steine, Jürgen Geisler, Torbjørn Omland
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 6, Iss 11 (2017)
BackgroundAnthracyclines are associated with cardiotoxic effects. Cardiovascular biomarkers may reflect myocardial injury, dysfunction, inflammation, and fibrosis and may precede and predict the development of left ventricular impairment. The aim of
Externí odkaz:
https://doaj.org/article/fa4d943f76444ab399489cb7d2481be1
Publikováno v:
JACC: CardioOncology. 4:19-37
Cardiotoxicity is a relatively frequent and potentially serious side effect of traditional and targeted cancer therapies. Both general measures and specific pharmacologic cardioprotective interventions as well as imaging- and biomarker-based surveill
Autor:
Vilde Drageset Haakensen, Sigrun Halvorsen, Henrik Horndalsveen, Kristin Holm Tjessem, Geeta Gulati
Publikováno v:
Tidsskrift for Den norske legeforening.
Immunologiske sjekkpunkthemmere har vært revolusjonerende innen kreftbehandlingen. En sjelden, men alvorlig bivirkning er utviklingen av hjertemuskelbetennelse (myokarditt). Forekomsten av denne typen myokarditt er økende etter hvert som flere kref
Autor:
Geeta Gulati
Publikováno v:
European Heart Journal. 43:2570-2572
Autor:
Sofie A Gevaert, Sigrun Halvorsen, Peter R Sinnaeve, Antonia Sambola, Geeta Gulati, Patrizio Lancellotti, Peter Van Der Meer, Alexander R Lyon, Dimitrios Farmakis, Geraldine Lee, Giuseppe Boriani, Ashutosh Wechalekar, Alicia Okines, Riccardo Asteggiano, Alain Combes, Roman Pfister, Jutta Bergler-Klein, Maddalena Lettino
Advances in treatment, common cardiovascular (CV) risk factors and the ageing of the population have led to an increasing number of cancer patients presenting with acute CV diseases. These events may be related to cancer itself or cancer treatment. A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f08e6500e932b3fd91c9f29d988a938
https://hdl.handle.net/11380/1292825
https://hdl.handle.net/11380/1292825
Autor:
Suvi Tuohinen, Agnes Smáradóttir, Agneta Månsson Broberg, Marianne Jarfelt, Tanja Skyttä, Jürgen Geisler, Geeta Gulati, Birgitte Vrou Offersen, Kirsten Nielsen, þórdís Jóna Hrafnkelsdóttir
Publikováno v:
JACC: CardioOncology
JACC. CardioOncology, Vol 2, Iss 2, Pp 333-335 (2020)
JACC. CardioOncology, Vol 2, Iss 2, Pp 333-335 (2020)
Cardio-oncology is a relatively new, albeit quickly expanding field. The efficacy of modern cancer therapy has increased the number of long-term cancer survivors. However, the long-term survival for cancer patients may in some cases be limited by car
Autor:
E Holte, Morten W. Fagerland, E S Blix, T Wethal, Albulena Mecinaj, Geeta Gulati, T Omland, Siri Lagethon Heck, Jürgen Geisler, Alf Inge Larsen
Publikováno v:
Cardio-oncology
Cardio-Oncology, Vol 7, Iss 1, Pp 1-11 (2021)
Cardio-Oncology, Vol 7, Iss 1, Pp 1-11 (2021)
Background Recent advances in the treatment algorithms of early breast cancer have markedly improved overall survival. However, anthracycline- and trastuzumab-associated cardiotoxicity may lead to dose-reduction or halt in potentially life-saving adj
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2694e5bb093c8b9039ae70a752c80e38
https://hdl.handle.net/11250/2992341
https://hdl.handle.net/11250/2992341
Autor:
Morten W. Fagerland, Geeta Gulati, Jeanette Schulz-Menger, Siri Lagethon Heck, Helge Røsjø, Pavel Hoffmann, Kjetil Steine, Jürgen Geisler, Anne Hansen Ree, Torbjørn Omland, Berit Gravdehaug, Albulena Mecinaj
Background: Adjuvant breast cancer therapy containing anthracyclines with or without anti–human epidermal growth factor receptor–2 antibodies and radiotherapy is associated with cancer treatment–related cardiac dysfunction. In the PRADA trial (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::756db752292dc2b789651522e3139043
http://hdl.handle.net/10852/90187
http://hdl.handle.net/10852/90187
Autor:
Alicia Okines, Sofie Gevaert, Alexander R. Lyon, Sigrun Halvorsen, Geraldine Lee, Antonia Sambola, Giuseppe Boriani, Peter Sinnaeve, Peter van der Meer, Dimitrios Farmakis, Geeta Gulati, Ashutosh D. Wechalekar, Patrizio Lancellotti, Riccardo Asteggiano
Publikováno v:
European Heart Journal: Acute Cardiovascular Care, 10(8), 947-959. SAGE Publications Inc.
BASE-Bielefeld Academic Search Engine
BASE-Bielefeld Academic Search Engine
Advances in treatment, common cardiovascular (CV) risk factors and the ageing of the population have led to an increasing number of cancer patients presenting with acute CV diseases. These events may be related to the cancer itself or the cancer trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::baaa458e0986985989094a3585d8e635
https://hdl.handle.net/11380/1256226
https://hdl.handle.net/11380/1256226